AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tivic Health Systems Reports Q2 2025 Earnings, Focuses on Prescription Therapeutics, Secures Exclusive License for TLR5 Agonist Platform, and Strengthens Cash Position.
ByAinvest
Friday, Aug 15, 2025 11:20 am ET1min read
Tivic Health Systems reported Q2 2025 earnings with revenue of $86,000, a gross margin of 63%, and a net loss of $1.9 million. The company plans to exit the consumer health technology business and focus on prescription-based therapeutics. Tivic obtained an exclusive license for Sotero Biopharma's TLR5 agonist portfolio, including late-stage entolimod and Entelaspa candidates. Entolimod has fast track designation for ARS and orphan drug status for pediatric ARS.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet